ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.779,54
-0,58%
S&P 500
5.306,04
0,02%
US Dollar vs BRL
5,1629
0,00%
Bitcoin
68.526,54
0,34%
Brent Oil
84,175
-0,18%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Surface Oncology Inc (SURF)

  7. Surface Oncology Inc (SURF) Notícias

SURF

Surface Oncology (SURF)

Surface Oncology Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SURF
DataHoraFonteTítuloCódigoCompanhia
13/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SURFSurface Oncology Inc
08/09/202317:10Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SURFSurface Oncology Inc
08/09/202317:04Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SURFSurface Oncology Inc
08/09/202317:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SURFSurface Oncology Inc
08/09/202310:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SURFSurface Oncology Inc
31/08/202318:18Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SURFSurface Oncology Inc
31/08/202317:01GlobeNewswire Inc.Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciencesNASDAQ:SURFSurface Oncology Inc
30/08/202317:32Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SURFSurface Oncology Inc
02/08/202308:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SURFSurface Oncology Inc
02/08/202308:00GlobeNewswire Inc.Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023NASDAQ:SURFSurface Oncology Inc
26/07/202317:56Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:SURFSurface Oncology Inc
20/07/202309:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SURFSurface Oncology Inc
16/06/202318:22Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SURFSurface Oncology Inc
16/06/202308:46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SURFSurface Oncology Inc
16/06/202308:01GlobeNewswire Inc.Coherus to Acquire Surface OncologyNASDAQ:SURFSurface Oncology Inc
17/05/202310:06Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SURFSurface Oncology Inc
04/05/202308:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SURFSurface Oncology Inc
04/05/202308:00GlobeNewswire Inc.Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023NASDAQ:SURFSurface Oncology Inc
01/05/202317:32Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:SURFSurface Oncology Inc
18/04/202308:00GlobeNewswire Inc.Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023NASDAQ:SURFSurface Oncology Inc
16/03/202309:00GlobeNewswire Inc.Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 NASDAQ:SURFSurface Oncology Inc
09/03/202309:00GlobeNewswire Inc.Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022NASDAQ:SURFSurface Oncology Inc
28/02/202318:15GlobeNewswire Inc.Surface Oncology to Participate in the Cowen 43rd Annual Health Care ConferenceNASDAQ:SURFSurface Oncology Inc
13/02/202316:09Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SURFSurface Oncology Inc
02/02/202310:00GlobeNewswire Inc.Surface Oncology to Participate in the 2023 Guggenheim Oncology Days ConferenceNASDAQ:SURFSurface Oncology Inc
05/01/202309:30GlobeNewswire Inc.Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid TumorsNASDAQ:SURFSurface Oncology Inc
07/11/202210:00GlobeNewswire Inc.Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual MeetingNASDAQ:SURFSurface Oncology Inc
03/11/202207:25TipRanksH.C. Wainwright Keeps Their Buy Rating on Surface Oncology (SURF)NASDAQ:SURFSurface Oncology Inc
02/11/202214:00TipRanksAnalysts’ Top Healthcare Picks: LivaNova (LIVN), Surface Oncology (SURF)NASDAQ:SURFSurface Oncology Inc
02/11/202207:30GlobeNewswire Inc.Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination CohortNASDAQ:SURFSurface Oncology Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SURF

Seu Histórico Recente

BOV
COGN3
COGNA ON
BOV
HBOR3
HELBOR ON
BOV
LUPA3
LUPATECH ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
OIBR3
OI ON
BOV
BLAU3
Blau Farmaceutica ON
BOV
INBR32
Inter &
BOV
GFSA3
GAFISA ON
BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados